Asunto(s)
Sistemas de Registro de Reacción Adversa a Medicamentos/normas , Recolección de Datos/estadística & datos numéricos , Interpretación Estadística de Datos , Inmunización/efectos adversos , Meningitis Aséptica/etiología , Humanos , Vacuna contra el Sarampión-Parotiditis-Rubéola/efectos adversos , Meningitis Aséptica/epidemiología , Meningitis Aséptica/fisiopatología , Seguridad , Vacuna contra Viruela/efectos adversos , Terminología como AsuntoRESUMEN
Millions of vaccine doses are wasted each year due to a lapse in recommended storage conditions. Maintaining the cold chain for vaccines is both expensive and difficult, especially in developing countries. The present study investigated the safety and immunogenicity of a single dose of the conjugated meningococcal Group C vaccine, Menjugate, stored for 6 months at room temperature (25+/-2 degrees C, N=250) or at 2-8 degrees C (N=250) when administered to 12-23 months toddlers. In the two respective groups, 87 and 88% of toddlers reached bactericidal antibodies titers of at least 1:8. The immunogenicity of Menjugate stored at room temperature was not inferior to that stored at 2-8 degrees C. The safety profile and immunogenicity of the vaccine was not influenced by the storage condition.
Asunto(s)
Vacunas Meningococicas/inmunología , Neisseria meningitidis Serogrupo C/inmunología , Anticuerpos Antibacterianos/análisis , Anticuerpos Antibacterianos/biosíntesis , Frío , Método Doble Ciego , Estabilidad de Medicamentos , Almacenaje de Medicamentos , Femenino , Liofilización , Humanos , Lactante , Masculino , Vacunas Meningococicas/efectos adversos , Vacunas Meningococicas/química , Temperatura , Vacunas Conjugadas/efectos adversos , Vacunas Conjugadas/química , Vacunas Conjugadas/inmunologíaRESUMEN
Two tick-borne encephalitis vaccines produced by two vaccine manufacturers are available in most European countries. A question that is frequently asked regarding these two vaccines concerns their exchangeability, however, to date, no detailed assessment has been published. This review analyzes clinical studies investigating these two vaccines and describes possible approaches to boost or continue uncompleted primary immunization schedules, with either of the two tick-borne encephalitis vaccines.
Asunto(s)
Virus de la Encefalitis/inmunología , Encefalitis Transmitida por Garrapatas/inmunología , Vacunas Virales/clasificación , Humanos , Esquemas de Inmunización , Inmunización Secundaria , Vacunas contra la Encefalitis Japonesa/clasificación , Vacunas de Productos InactivadosRESUMEN
Tick-borne encephalitis can be prevented by active immunization, for which different schedules and booster recommendations exist. However, recommended booster intervals are often exceeded. In the present study, 178 adults aged 18-81 years received the first booster dose 2-11 years after primary immunization (instead of 12-18 months as recommended) according to the rapid schedule (vaccination on days 0, 7, and 21). The booster dose was well tolerated. All subjects showed a typical anamnestic response with an 11-fold increase in the geometric mean titre as measured both by neutralization test and ELISA.
